Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

By: Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation [issuing body.]Contributor(s): Olson, Steve, 1956- [contributor.] | Claiborne, Anne B [contributor.] | National Institute of Medicine (U.S.). Board on Health Sciences Policy [issuing body.]Material type: TextTextPublisher: Washington, District of Columbia : National Academies Press, [2012]Copyright date: 2012Description: 1 online resource (131 pages)Content type: text Media type: computer Carrier type: online resourceISBN: 9780309261173Other title: Accelerating the development of new drugs and diagnosticsSubject(s): United States. Institutes of Health. National Center for Advancing Translational Sciences. Cures Acceleration Network | Drug monitoring | Drug development -- United States | Drugs -- United States -- Design | Pharmaceutical industry -- United States -- Quality controlGenre/Form: Electronic books.Additional physical formats: Print version:: Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary.DDC classification: 615.1/9 LOC classification: RM302 | .I58 2012Online resources: Click to View
Contents:
Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.
Summary: Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Includes bibliographical references (pages 71).

Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.

Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.

Description based on print version record.

Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.

There are no comments on this title.

to post a comment.